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Abstract: Background: Tart Montmorency cherries (MC) have been shown to be rich in anthocyanins
and other phytochemicals known to have anti-inflammatory properties and influence pathways that
might improve cardiometabolic health. However, there is limited evidence for the longer-term use
of tart cherries on these indices. The aim of the current study was to investigate the influence of
MC concentrate on cardiometabolic health indices following a 3-month supplementation period.
Methods: Fifty middle-aged adults (34 males and 16 females; mean ± SD age: 48 ± 6 years and BMI:
27.6 ± 3.7 kg/m2) completed a randomised, placebo-controlled parallel study in which they either
received MC or an isocaloric placebo. Participants drank 30 mL of their allocated treatment twice per
day for 3 months. Vascular function (blood pressure [BP], heart rate [HR], pulse wave velocity and
analysis [PWV/A], and flow mediated dilation [FMD]) as well as indices of metabolic health (insulin,
glucose, lipid profiles, and high sensitivity C reactive protein) were measured following an overnight
fast before and after the 3 months. Results: No effect of the intervention between the groups was
observed for vascular function or metabolic health variables following the intervention (p > 0.05).
However, MC concentrate was shown to be safe and well-tolerated and, importantly, did not have
any deleterious effects on these outcomes. In conclusion, MC has no influence on cardiometabolic
indices in middle-aged adults.
Keywords: tart cherry; cardiovascular disease; vascular function; metabolic health
1. Introduction
Recent advances in technology and medicine have resulted in increased life expectancy
and an aging population; it is now estimated that non-communicable diseases account for
71% of all deaths globally [1]. Cardiovascular disease (CVD) and type 2 diabetes combined
are the primary cause of global mortality, increasing in prevalence with age [2]. Midlife
risk factors have been proposed to underlie the development of these diseases, which
evolve over years or decades before the emergence of clinical manifestations [3–5]. Thus,
midlife has consistently been highlighted as a pivotal period for lifestyle interventions to
improve health, reduce disease trajectory, and to promote healthy aging [6,7]. For exam-
ple, middle-aged individuals who decrease their blood pressure (BP) to normal ranges
(<120/<80 mmHg) have a significantly lower risk of CVD in their remaining lifetime com-
pared with those with hypertension [8]. Furthermore, oxidative stress and inflammation
are key mechanisms of endothelial dysfunction and arterial damage; thus, they are linked
to type 2 diabetes [9] and CVD [4]. Consequently, there has been a research emphasis in
natural dietary sources of antioxidants and foods with anti-inflammatory properties [10].
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There is accumulating evidence that tart Montmorency cherries (MC) can positively
impact cardiometabolic risk factors that include antioxidant [11], anti-inflammatory [12],
and antihypertensive properties [13–15]. Tart MC are a relatively abundant source of
anthocyanins [16]; the polyphenols responsible for the red-blue-purple pigmentation in
fruit and vegetables. Previous work from our research group has shown that the higher
intake of dietary anthocyanins is inversely associated with the risk of CVD mortality [17],
and cherries have been reported to account for a considerable dietary intake of these
compounds [18–20]. In vitro anthocyanin metabolites have been shown to interact with
vascular smooth muscle cells [21] and upregulate endothelial nitric oxide synthase (eNOS)
in endothelial cells [22]. More recently, the anthocyanin metabolites following blueberry
intake were associated with improved endothelial function and nitric oxide (NO) bioavail-
ability and were shown to influence genes involved in the regulation of cell adhesion, cell
migration, inflammation, and cell differentiation processes, conferring the cardioprotective
properties of these compounds [23].
Furthermore, MC are also rich in other phytochemicals (e.g., phenolic acids, flavonols,
flavon-3-ols, melatonin, and carotenoids) that might have synergistic and additive effects
on any bioactivities, including their antioxidant and anti-inflammatory actions [21,24].
Nonetheless, despite some promising epidemiological and in vitro studies suggesting a
putative role for MC in cardiovascular and metabolic health, clinical trials have provided
paradoxical and equivocal findings for any benefits associated with their intake. For
example, relatively short-term (4–6 week) MC interventions failed to influence endothe-
lial function, blood pressure, and cholesterol in middle-aged populations [11,12,25,26].
However, a longer-term (12 week) consumption of MC juice has been shown to reduce
systolic BP and low-density lipoprotein (LDL) in older adults [14]. Moreover, Johnson
and colleagues [27] demonstrated that 12, but not 6, weeks of MC reduce oxidised LDL in
individuals with metabolic syndrome. To date, there has been no study investigating the
longer-term influence of MC on cardiometabolic risk factors in a middle-aged population;
however, based on recent findings, it was hypothesised that longer-term MC supplemen-
tation would improve vascular function and metabolic health parameters. Therefore, the
aim of the current study was to investigate the influence of 3 months of MC concentrate
supplementation on cardiometabolic health indices in middle-aged adults.
2. Materials and Methods
2.1. Participants
Non-smoking males and females between the ages of 40 to 60 years were recruited
from Newcastle Upon Tyne and the local area of the city, using posters, email distributions,
social media, and word of mouth. To be included in the study, participants must have
reported to consume (on average) less than 5 servings of fruits and vegetables per day,
did ≤4 h of moderate–vigorous physical activity per week, and had a ≥1 risk factor for
type 2 diabetes. These risk factors included body mass index (BMI) >25 kg/m2; waist
circumference >102 cm for males and >88 cm for females; family history of type 1 or type
2 diabetes; were a member of a type 2 diabetes high risk population (Aboriginal, Hispanic,
Asian, South Asian, or African decent) or were hypertensive; >140/90 mmHG [28,29]. All
participants were otherwise in apparent good health, as assessed by a health-screening
questionnaire, not regularly taking medication (or stabilised ≥3 months, with no adverse
symptoms) or antioxidant supplements and willing to report any changes in health status
or medication during the study period.
Exclusion criteria were defined as a history of cardiometabolic disease, uncontrolled
hypertension (SBP > 159 mmHg or DBP > 99 mmHg), gastrointestinal disease or mal-
absorption syndromes, reported changes in dietary or physical activity patterns within
3 months prior or intention to change during the study period, vegetarians, vegans or
had known eating disorders, excessive alcohol intake, or a BMI ≥40 kg/m2. Additionally,
participants who were pregnant or planning to become pregnant during the study, lactating,
or initiating or changing a hormone replacement therapy regimen within 3 months of the
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start of the study were also excluded. This study was conducted in accordance with the
Declaration of Helsinki and ratified by the University’s Research Ethics Committee prior to
participants providing written, informed consent. This study was registered as a clinical
trial with clinicaltrials.gov [NCT04021342].
2.2. Study Design
This study employed a randomised, double-blind, placebo-controlled, parallel design.
After screening and recruitment, participants were familiarised with the testing equipment
and procedures (visit 1). Following this, they were randomly assigned to receive either
MC concentrate or an isocaloric placebo for 3 months using a computer-generated plan
(https://www.randomization.com, accessed on 18 September 2018), stratified by sex.
The study comprised of two experimental visits, following a minimum of a 7-day low
anthocyanin run-in. Vascular function and metabolic health variables, as described below,
were assessed at baseline (visit 2; pre-supplementation) and at 3 months (visit 3; post-
supplementation). All experimental visits took place between 8:00 and 10:00 am and were
preceded by an overnight fast (≥10 h). Participants were also asked to arrive hydrated
and to avoid strenuous exercise, alcohol, and nutritional supplements 24 h and caffeine
12 h prior.
2.3. Dietary Intervention
A concentrated MC juice stored at 4 ◦C was used in this study. The concentrate
was provided by Cherry Marketing Institute (USA). The participants were instructed to
consume either 30 mL of MC concentrate diluted in 240 mL of water or the same volume
of placebo twice daily; once in the morning and again in the evening. According to the
manufacturers, this is the equivalent of ~180 cherries per day. Previous batch analysis
by our laboratory, using the pH differential method and the modified Folin-Ciocalteu
colorimetric method, showed that 60 mL of MC concentrate is the equivalent to 68–73.5 mg
of anthocyanins and 160.8–178.8 mg of total phenolics, respectively [13,30]. The placebo was
prepared by mixing unsweetened black cherry flavoured Kool-Aid (Kraft Foods, United
States), dextrose (MyProtein Ltd., Northwich, UK), and fructose (Sports Supplements Ltd.,
Essex, UK) with bottled water to best match the calorie content of the MC concentrate
(Energy = 102 kcal, volume = 30 mL, carbohydrates = 25.5 g, protein = 0 g and fat = 0 g).
Additional lemon juice (which is not known to contain anthocyanins [31]), for tartness and
preservation, and artificial food colouring were added so that the final product had the
same visual properties [14,32]. The assigned treatment and a 30 mL measuring cup were
supplied to the participants by a researcher (independent to the project) to ensure the study
remained double-blinded. Compliance was measured by daily tick sheets and return of
any unconsumed juice. To evaluate blinding efficacy, the participants were asked to guess
which treatment they thought they had been taking, following the supplementation period.
Throughout the study, the participants were encouraged to maintain their habitual
diet and exercise routines; however, they were asked to refrain from consuming cherries,
cherry products, or any antioxidant supplements. Additionally, they were given verbal and
written instructions to limit berry fruits, red grapes (including extracts and juices), and red
wine (which are the highest contributors of dietary anthocyanins [18,19]) to ≤1 portion per
day throughout the study period. The participants recorded their pre-evening meal before
the first experimental visit and were asked to replicate this before the second experimental
visit. To monitor dietary intake, the participants recorded a 3-day food and exercise diary
(two consecutive weekdays and one weekend day), which was analysed retrospectively
(Nutritics software, v5.09, Dublin, Ireland). They also completed the International Physical
Activity Questionnaire (IPAQ) and a short form quality-of-life survey (SF-36 [33]) at the
beginning and end of the study, to determine physical activity levels and tolerance to the
intervention, respectively.
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2.4. Anthropometry and Aerobic Capacity
Stature was measured to the nearest 0.1 cm, using a stadiometer, and body mass
measured to the nearest 0.1 kg, using the same digital scale (Seca Scales 703, Seca Ltd.
Birmingham, UK). Body composition (fat mass, fat percentage, and lean body mass) was
measured by dual-energy X-ray absorptiometry (DXA; Hologic, Horizon, Manchester, UK).
The scanner was calibrated before each assessment in accordance with the manufacturer’s
guidelines, and participants were instructed to wear the same clothing for each visit.
Adiposity distribution is also reported, where the android and gynoid regions of the trunk
were defined by the Hologic APEX software (version 5.6) and the percentage fat of each
region used to calculate the android/gynoid ratio. Exercise capacity (V̇O2 max) was also
assessed before and after the intervention, using a sub-maximal cycle test; the Astrand-
Rhyming single-stage, 6-min test [34,35]. All measurements were performed at baseline
and on the return visit, 3 months later.
2.5. Vascular Function
Vascular function was assessed, as previously described, with participants in the
supine position [36]. Briefly, BP and heart rate (HR) were measured using a non-invasive,
automated vital signs monitor (Carescape V100; Dinamap), closely adhering to the guide-
lines specified by the European Society of Hypertension [37]. Peripheral BP measurements
were taken in triplicate, each separated by 1 min [38], and the mean of the last 2 readings
of systolic (SBP), diastolic (DBP), and HR were used for analysis (coefficient of variation;
CV < 6%).
The pulse wave velocity and analysis (PWV/A) were determined through arterial
tonometry, using the SphygmoCor CPV system (ScanMed Medical, Moreton in Marsh,
UK). The PWV (in m/s) was determined between carotid and femoral sites with electro-
cardiogram gating. The PWA was recorded at the radial artery, and the corresponding
augmentation index (AIx) was derived, using a generalised transfer function [39]. The AIx
is influenced by heart rate [40]; therefore, the Aix, normalised for a standard heart rate of
75 bpm (AIx@75), was also measured. The SphygmoCor software (version 9.0, ScanMed
Medical, Moreton in Marsh, UK) provides indices of quality control; if the measurement
did not meet these control criteria, it was discarded and replaced by a new measurement.
A minimum of two acceptable readings was obtained for both PWV and PWA and the
average used for analysis.
Brachial artery flow mediated dilation (FMD) was acquired using ultrasonography
(HDI-5000 SONO CT ultrasound machine; Philips Medical System). The resting baseline
diameter was recorded for 1 min prior to occlusion of the artery, which was obtained by
inflating a manual sphygmomanometer >50 mmHg above SBP. Occlusion of the artery
was maintained for 5 min. The recording was resumed 1 min before deflating the cuff and
3 min thereafter. The average baseline resting diameter and peak diameter post-occlusion
were determined, using semi-automated computer software (Brachial Analyzer; Medical
Imaging Applications), which were used to calculate the percentage FMD.
2.6. Haematological Samples
Venous blood samples (~12 mL) were collected in lithium-heparin vacutainers (Becton,
Dickinson and Company, Plymouth, UK). Due to sampling errors, samples were available
for 40 participants (Cherry n = 19; Placebo n = 21). These were centrifuged at 3000× g
(4 ◦C) for 10 min and the plasma aliquoted and stored at −80 ◦C to be analysed later.
Plasma samples were analysed for cholesterol, high density lipoprotein (HDL) cholesterol,
triglycerides, and glucose, using a colorimetric enzymatic method (CV < 3.7 %). Insulin was
analysed using enzyme-linked immunosorbent assay (Mercodia, Sweden; CV = 12%). High
sensitivity CRP (hs-CRP) was analysed using particle-enhanced immunoturbidimetric
assay (CV = 7.8%). The non-HDL cholesterol was calculated as HDL subtracted from total
cholesterol. The LDL cholesterol was calculated using the Friedewald equation [41]. The
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homeostatic model assessment of insulin resistance (HOMA-IR) was calculated, according
to Matthews et al. [42], using the following formula:
HOMA-IR = (Fasting insulin × Fasting glucose)/405 (1)
2.7. Power Calculation and Statistical Analysis
Power calculations were performed for the primary end point: change in SBP after
3 months of consumption. The power was based on the inter-individual variability for SBP
measurement [36]; assuming an 80% power and a 0.05 significance level, the total number
of subjects required to provide sufficient power to detect a 5 mmHg, a clinically meaningful
amount [43] in a 2-arm, parallel study was estimated to be 50. A total of 60 participants
were needed to allow for a 20% drop-out; however, only 56 were recruited before the
study end.
All data were analysed using IBM SPSS statistics (v 26.0 for Windows; SPSS, Chicago,
IL, USA), measures are reported as means ± standard deviation (SD) in tables and standard
error (SE) in figures, unless otherwise stated. The normality of distribution for outcome
measures was tested using the Shapiro Wilks test, and the assumptions were tested prior
to analysis. Baseline characteristics were compared by Wilcoxon signed-rank test where
data were continuous, and Chi-square test where data were categorical. Dietary, physical
activity and SF-36 data were analysed using a two-way (treatment × time) analysis of
variance (ANOVA). Treatment guess data were analysed by Chi-square test. The effect
of the intervention on vascular function and metabolic health variables was evaluated
using a one-way analysis of covariance (ANCOVA), adjusted for baseline [44]. Additional
covariates of sex and use of medication were added into the analysis for the primary
outcome (vascular function). For blood samples, where values fell below the limits of
detection, the sensitivity threshold of the assay was used to maintain participant numbers.
The hs-CRP, HOMA-IR, and insulin values were non-normally distributed; thus, they were
log transformed before analysis. Sidak adjusted post hoc comparisons were then carried
out between cherry juice and placebo, as appropriate.
3. Results
A total of 56 individuals were enrolled in the study and randomised to the inter-
vention (Figure 1). There was no difference between the group characteristics at baseline
(Table 1). Three participants from each group did not complete the study, as shown in
Figure 1. One participant in the cherry group discontinued the juice and withdrew from
the study due to gastrointestinal discomfort and bloating. The treatments were otherwise
well-tolerated, as suggested by the SF-36, which showed no treatment, time, or interaction
differences between the groups (data not shown). The mean (± SD) self-reported compli-
ance (as assessed by tick sheets) was 94 ± 9% and 98 ± 4% in the cherry and placebo group,
respectively. Five participants (20%) correctly guessed that they were in the placebo group;
however, the Chi-square test suggested successful blinding (p = 0.386).
3.1. Physical Activity, Diet, and Body Composition
There was no treatment, time, or treatment × time interaction effects observed for
physical activity, sitting time, or exercise capacity (Table 2). The analysis of 3-day diet
records showed that there were no differences between the two groups for the mean intake
of total energy, fat, or saturated fat intake. Protein intake showed a treatment × time
interaction (F = 7.8, p = 0.011). Planned post hoc tests revealed that protein intake at
baseline was, on average, 12 g higher in the placebo group compared with the cherry group
(F = 6.7, p = 0.016). There was also an increase in carbohydrate (36 g) intake at 3 months in
both groups, with a main effect of time (F = 17.3, p < 0.001). Body mass (F = 8.5, p = 0.007),
BMI (F = 12.6, p = 0.002), and fat mass (F = 4.8, p = 0.040) increased relative to baseline in the
placebo group, main effect of time. Fat mass (F = 7.7, p = 0.011) and fat percentage (F = 4.38,
p = 0.047) also increased after 3 months in the cherry group. There was no treatment
effect observed at baseline or after 3 months for body mass. There was no treatment,
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time, or treatment × time interaction effects between lean mass or android/gynoid ratio
(Table 2).
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Body Mass (kg) 81.8 ± 12.9 81.7 ± 14.0 82.0 ± 11.9 0.793 
BMI (kg/m2) 27.3 ± 3.7 27.0 ± 3.8 27.4 ± 3.7 0.569 
Ethnicity (n; %)    0.368 
White  54 (96.4) 27 (96.4) 27 (96.4)  
Education (n; %)    0.798 
Less Than High School − − −  
High School or Equivalent 24 (43) 11 (39) 13 (46)  
Bachelor’s Degree 19 (34) 9 (32) 10 (36)  
Postgraduate Degree 13 (23) 8 (29) 5 (18)  
Medication (n; %) 17 (30) 10 (36) 7 (25) 0.771 
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Baseline 2462 ± 2038 1953 ± 1527 0 267 0.959 0.961
3 months 2464 ± 2336 1978 ± 1217
Sitting time (h)
Baseline 6.6 ± 3.1 6.7 ± 3.0 0.856 0.852 0.486
3 months 6.7 ± 2.8 6.3 ± 3.0






Baseline 35.9 ± 11.1 37.3 ± 7.5 0.319 0.187 0.386
3 months 33.7 ± 9.6 37.1 ± 6.2
Energy (Kcal)
Baseline 1921 ± 340 1896 ± 439 0.997 0.212 0.673
3 months 1977 ± 439 2001 ± 423
Carbohydrates (g)
Baseline 208.8 ± 38.6 196.1 ± 47.3 0.671 <0.001 0.350
3 months 237.3 ± 70.0 # 239.6 ± 66.7 #
Fat (g)
Baseline 76.5 ± 18.5 78.4 ± 24.2 0.681 0.231 0.999
3 months 72.1 ± 18.1 74.1 ± 21.2
Saturated fat (g)
Baseline 28.2 ± 8.6 27.5 ± 8.0 0.849 0.224 0.836
3 months 25.8 ± 8.3 25.7 ± 10.6
Protein (g)
Baseline 80.2 ± 21.9 92.3 ± 16.9 * 0.193 0.051 0.006
3 months 80.3 ± 15.7 78.5 ± 19.3 #
Body mass (kg)
Baseline 82.8 ± 13.9 82.4 ± 12.3 0.968 0.007 0.048
3 months 83.4 ± 14.2 84.1 ± 13.2 #
BMI (kg/m2)
Baseline 27.3 ± 3.8 27.5 ± 3.8 0.757 0.001 0.057
3 months 27.5 ± 3.8 28.1 ± 4.0 #
Body fat (%)
Baseline 37.1 ± 7.9 36.1 ± 6.8 0.642 0.031 0.862
3 months 37.7 ± 6.8 # 36.7 ± 6.8
Fat mass (kg)
Baseline 30.2 ± 9.1 29.6 ± 7.1 0.856 0.007 0.691
3 months 31.1 ± 9.5 # 30.7 ± 7.5 #
Lean mass (kg)
Baseline 48.1 ± 9.4 49.8 ± 8.5 0.360 0.248 0.199
3 months 48.1 ± 8.5 50.4 ± 9.2
Android/gynoid ratio
Baseline 1.09 ± 0.17 1.13 ± 0.18 0.394 0.403 0.529
3 months 1.08 ± 0.17 1.13 ± 0.18
Mean ± SD; body mass index (BMI); # significantly different from baseline; * significantly different between groups (p < 0.05).
3.2. Influence of MC on Vascular Function
After adjusting the baseline (pre-treatment) values, sex, and medication, there were no
group differences between MC and placebo at 3 months for SBP (117 ± 14 vs. 118 ± 11 mmHg;
p = 0.8; Figure 2). After 3 months, there was also no difference for DBP, HR, arterial stiffness
(PWV, AIx and AIx@75), or endothelial function (FMD), compared to the placebo (Table 3).
3.3. Influence of MC on Metabolic Health Indices
After adjusting the baseline (pre-treatment) values, there were no group differences
between cherry juice and placebo for lipid profiles, insulin, glucose, HOMA-IR, or hs-CRP
(Table 4).
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pressure (DBP); flow-mediated dilation (FMD); heart rate (HR); pulse wave velocity (PWV). 
Figure 2. Systolic blood pressure before (left) and after 3-month supplementation (right) with cherry
juice (A) and placebo (B).
Ta le . Infl e ce f tart t r i l
Cherry
Juice Placebo
ANCOVA Adjusted for Baseline Adjusted for Baseline, Sex andMedication
Difference
(95% CI) F p-Value
Difference
(95% CI) F p-Value
SBP (mmHg)
Baseline 120 ± 15 119 ± 11 −0.5 (−4.9, 3.8) 0.056 0.814 −0.6 (−5.1, 3.9) 0.079 0.780
3 months 117 ± 14 118 ± 11
DBP (mmHg)
Baseline 73 ± 10 73 ± 8 −0.4 (−3.0, 2.3) 0.086 0.770 −0.5 (−3.1, 2.2) 0.127 0.723
3 months 73 ± 9 73 ± 8
HR (BPM)
Baseline 59 ± 11 59 ± 10 −0.3 (−3.7, 3.1) 0.033 0.858 0.2 (−3.6, 3.2) 0.014 0.908
3 months 59 ± 12 59 ± 10
PWV (m/s)
Baseline 6.7 ± 1.0 6.4 ± 0.8 0.3 (−0.3, 0.8) 1.051 0.312 0.2 (−0.2, 0.7) 0.967 0.332
3 months 6.8 ± 1.3 6.2 ± 0.8
AIx (%)
Baseline 22.1 ± 8.9 17.8 ± 11.4 0.3 (−3.6, 4.2) 0.021 0.886 0.3 (−3.6, 4.2) 0.022 0.884
3 months 20.4 ± 9.6 17.0 ± 10.0
AIx@75 (%)
Baseline 13.4 ± 8.1 9.6 ± 12.9 0.02 (−3.6, 3.6) <0.001 0.991 −0.06 (−3.6,3.5) 0.001 0.937
3 months 12.3 ± 9.2 9.3 ± 11.0
FMD (%)
Baseline 8.3 ± 3.5 9.3 ± 3.5 1.1 (−1.1, 3.3) 0.972 0.330 1.2 (−1.0, 3.3) 1.256 0.269
3 months 9.7 ± 3.5 9.0 ± 4.0
Mean ± SD; Abbreviations; augmentation index (AIx); AIx normalised for a heart rate of 75 bpm (AIx@75); diastolic blood pressure (DBP);
flow-mediated dilation (FMD); heart rate (HR); pulse wave velocity (PWV).
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ANCOVA Adjusted for Baseline
Difference
(95% CI) F p-Value
Insulin (pmol/L)
Baseline 20.3 ± 15.4 19.6 ± 10.2 −0.01 (−0.18, 0.15) 0.020 0.888
3 months 17.8 ± 10.0 19.0 ± 13.0
Glucose (mmol/L)
Baseline 5.4 ± 0.5 5.5 ± 0.5 −0.01 (−0.21, 0.18) 0.016 0.899
3 months 5.4 ± 0.5 5.4 ± 0.3
HOMA-IR
Baseline 0.7 ± 0.6 0.7 ± 0.4 0.04 (−0.13, 0.21) 0.239 0.629
3 months 0.7 ± 0.4 0.7 ± 0.5
hs-CRP (mg/L)
Baseline 1.6 ± 2.3 1.2 ± 1.2 −0.003 (−0.14, 0.14) 0.111 0.741
3 months 1.4 ± 1.7 1.2 ± 1.0
Triglycerides (mmol/L)
Baseline 1.2 ± 0.6 1.2 ± 0.7 −0.06 (−0.29, 0.18) 0.241 0.627
3 months 1.2 ± 0.7 1.3 ± 0.7
Cholesterol (mmol/L)
Baseline 5.3 ± 1.2 5.0 ± 1.0 −0.15 (−0.51, 0.21) 0.728 0.399
3 months 5.2 ± 1.1 5.1 ± 0.9
LDL Cholesterol
(mmol/L)
Baseline 3.2 ± 1.0 3.0 ± 1.0 −0.09 (−0.38, 0.20) 0.411 0.525
3 months 3.1 ± 1.0 3.1 ± 1.0
HDL Cholesterol
(mmol/L)
Baseline 1.6 ± 0.3 1.5 ± 0.4 −0.02 (−0.15, 0.12) 0.061 0.806
3 months 1.5 ± 0.4 1.5 ± 0.4
Non-HDL Cholesterol
(mmol/L)
Baseline 3.7 ± 1.2 3.5 ± 1.2 −0.17 (−0.49, 0.16) 1.08 0.305
3 months 3.7 ± 1.1 3.6 ± 1.1
Total/HDL Cholesterol
Ratio
Baseline 3.5 ± 1.0 3.7 ± 1.3 −0.076, −0.41, 0.26) 0.209 0.650
3 months 3.6 ± 1.2 3.8 ± 1.4
Mean ± SD. Abbreviations: high-density lipoproteins (HDL); homeostatic model assessment of insulin resistance (HOMA-IR); high-
sensitivity C-reactive protein (hs-CRP) log transformed before analysis; raw values are presented.
4. Discussion
To date, this is the largest and longest duration study to determine the influence of
MC on vascular function and metabolic health in free-living, middle-aged adults. The
primary aim was to assess any change in vascular function, specifically SBP, which was
shown to be modulated in previous work [14,30]. However, based on the vascular function
variables measured in the current study, and, contrary to the hypothesis, there was no
effect on BP, endothelial function, or arterial stiffness (Table 3). While the reasons for this
could be manifold, it might be explained by the kinetics of tart cherry phenolics. We and
others have previously shown that tart cherry anthocyanin metabolites peak in the plasma
within 1–2 h, a time course which coincides with the greatest reductions in postprandial
SBP [13,15,45]. Moreover, there is a rapid clearance in these metabolites, with SBP returning
to basal within 3–4 h [13,15]. In the current study, vascular function was measured after
an overnight fast; therefore, the peak vasomodulatory properties of the MC might have
been missed. This represents a limitation of the current study, as acute responses were not
investigated; however, the study was ultimately interested in the cumulative influence
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of MC consumption. In a recent addition to the literature, Desai and colleagues [46]
demonstrated that a 6-day supplementation with 30 mL MC had no influence on fasted or
post-bolus laboratory SBP; however, it did influence a 24 h ambulatory SBP after the 7th
day. These data could suggest a first dose phenomenon similar to that of antihypertensive
medications, in that the large fall in SBP is as an initial response to the peak tart cherry
phenolics but the magnitude of which is less pronounced over time [47].
In contrast to the current study, two randomised controlled studies have shown
that tart [14] and sweet cherry juice [48] reduce SBP in older adults, following a 12-week
supplementation. The reason for sustained changes in vascular function, following chronic
anthocyanin and other polyphenol supplementation, are currently unknown; however, they
are possibly mediated via the modulation of the microbiome and complex gene expression
alterations [23,49,50]. Therefore, the genetic changes and reductions in microbial diversity
that occur in older adults [51,52] might explain why the aforementioned studies [14,48]
found a beneficial effect of MC. However, in the current study, middle-aged adults likely
have higher numbers and diversity of protective microbial species [53,54]; hence, they
are less amenable to these changes [25]. Other potential reasons for these discrepancies
could be due to inter-individual differences in the response or initial vascular function of
the cohort. A recent review of the factors that influence the efficacy of anthocyanins on
BP regulation highlighted that baseline BP was an important factor, with changes only
evident in those with an elevated initial BP [55]. Despite recruiting middle-aged individuals
with additional risk-factors for CVD, the participants in the current study were either pre-
symptomatic or had controlled hypertension, thus had BP readings within the normal
range, whereas the older adults had higher BP at baseline. Moreover, the data in the present
study are in line with those of the others that longer tart cherry supplementation does not
influence resting SBP in normotensive individuals [11,56], even those with increased CVD
risk [12,27]; this suggests that the latter reason is the most probable one for the disparity
between the studies.
Endothelial dysfunction and arterial stiffness are indicators of subclinical atherosclero-
sis and precede hypertension; thus, they are major risk factors for CVD [57], though are
also modifiable by diet [3]. Here, we found no noteworthy changes in FMD, PWV, or PWA.
However, it should be acknowledged that the participants in the current study were on
medications, and these could have had an influence on these variables; although they were
included in the statistical analysis, they could have confounded the results. Nonetheless,
according to the HSE [58], nearly half (48%) of the adults in England are regularly taking
at least one prescription drug; therefore, the cohort in this study has general applicability
to the wider population. Importantly, our findings are consistent with the literature. For
example, Lynn and colleagues [11] reported no effect on brachial-knee PWV in healthy
middle-aged adults, following a 6-week supplementation with 30 mL MC concentrate, in an
open-labelled randomised controlled trial. Similarly, Johnson et al. [27] reported no effect
of a 12-week bi-daily MC consumption on Aix, when corrected for a HR of 75 beats/min or
PWV, in individuals with metabolic syndrome. Moreover, Aboo-Bakker et al. [26] demon-
strated that a 4-week supplementation of MC powder (256 mg/day anthocyanins split into
two doses, morning and evening) did not improve resting FMD; however, it did restore
FMD and enhance the recovery of plasma nitrite following occlusion-induced ischemia
reperfusion. Likewise, in clinical populations with greater impairment to vascular function,
anthocyanin-rich foods have been shown to improve these parameters [59–61]. Therefore,
while early intervention in at-risk individuals (such as those in the current study) remains
a research priority in reversing or reducing the disease risk trajectory preventing CVD, it is
plausible that improvements following MC intake in these individuals might require more
longitudinal observations. Those with pathological conditions might benefit more from MC
supplementation due to the systemic pro-inflammatory and pro-oxidative state associated
with these [62]. Likewise, those with hypertension or other cardiovascular dysfunctions
might benefit more. Therefore, future work could focus on these sorts of pathology to
examine this idea.
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The current study also identified no changes in the markers of metabolic health or
inflammation following the intervention (Table 4). These findings are not alone, given that
tart cherries have failed to influence cholesterol [11], insulin concentrations/resistance [63],
and markers of systemic inflammation [25] in similar populations. In the current study,
the levels of these markers before the intervention were all within normal ranges and thus,
similar to BP, less likely to benefit from an intervention, relative to those with elevated
baseline values, i.e., older individuals and those with metabolic or inflammatory condi-
tions [12,14,15,64]. Notably, despite the relatively high sugar content of the concentrate and
subsequent increase in carbohydrate intake over the intervention, there were no deleterious
influences on these outcomes in response to the additional glycaemic stress [65]. Moreover,
there is epidemiological evidence that suggests higher intake of dietary anthocyanins
is associated with reduced inflammation, insulin resistance, risk of type 2 diabetes, and
CVD [17,66,67]; therefore, again, we cannot rule out the influence of longer study durations.
It should be acknowledged that there was a marked effect of the intervention on
body composition in both groups. After 3 months, both body mass and BMI were higher
in the placebo group, whereas fat percentage was higher in the cherry group and fat
mass had increased in both groups (Table 2). In the current study, the MC concentrate
was given as an adjunct to the diet, as previous studies had suggested little influence
on body composition [12,27]. A limitation of the present study is that dietary records
and IPAQ were only collected at the beginning and end of the study, as opposed to
throughout; although total energy intake, physical activity, or exercise capacity did not
appear to change, we cannot rule out that changes may be seasonal and un-related to the
intervention [68]. However, future studies should adjust diet to accommodate calories
from juice, particularly since interventions demonstrate that energy from beverages leads
to little dietary compensation and results in weight gain because beverages possess poor
satiating properties compared to their solid equivalents [69]. Moreover, the changes in body
composition following MC intake are not in isolation. For example, Chai and colleagues [14]
reported a higher BMI (1.06 kg/m2) in those consuming MC concentrate for 12 weeks.
More recently, Dodier et al. [70] reported an increase in body mass and BMI, following
the intake of 240 mL/day of MC for 90 days, warranting careful consideration in future
research designs.
Due to the low number of adverse events, good compliance levels reported, and no
effect on quality-of-life indices, it is reasonable to suggest that cherry juice is a safe and
tolerable intervention, although future studies should consider dietary modification to
accommodate for the increase in Kcal from the juice. This study has several strengths
such that it was successfully blinded, sufficiently powered, of a longer-term duration, and
well-controlled, compared to other studies of a similar nature [11,14,15,62,71]. However,
there are other limitations that warrant discussion. Firstly, compliance to the intervention
was self-reported; as these were free-living adults, there was no control over whether they
adhered to the intervention, how they stored the concentrate, or when they consumed
the MC. Secondly, anthocyanin content is reported based on previous analysis, which
was conducted in our laboratory; however, batch-to-batch variation can naturally occur
due to growing conditions (e.g., soil, use of fertiliser, time of year, weather), storage, and
processing. Additionally, the lack of specific analytics [72] in the current study needs to
be considered while interpreting the findings. Lastly, BP was measured in the laboratory,
which was shown to be reliable; however, a 24 h ambulatory BP could be more advanta-
geous in establishing small changes in BP following MC supplementation [46], due to the
large number of readings and avoidance of ‘white-coat hypertension’.
5. Conclusions
In conclusion the current study found no effect of a 3-month MC concentrate on
vascular function and metabolic health indices. Given the current interest in the facilitation
of healthy aging, investigation into the intake of anthocyanin-rich foods such as MC, in pre-
symptomatic and at-risk individuals, are important as a means to preserve cardiometabolic
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health, although more longitudinal observations might be required. Future studies should
consider utilising populations with similar risk factors (e.g., hypertension) and impairments
in vascular and metabolic function at baseline, which could provide a suitable population
to examine the potential efficacy of foods rich in these compounds.
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